View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 10, 2019updated 24 Dec 2019 7:14am

Griffith University-led research projects secure funding from NHMRC

Griffith University-led research projects have received funding from the National Health and Medical Research Council (NHMRC).

Griffith University-led research projects have received funding from the National Health and Medical Research Council (NHMRC).

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The university noted that five of its projects from across the health and medical science fields received grants worth about $6.08m.

More than 400 Griffith’s new research projects are sharing $427m in NHMRC funding.

Griffith University acting deputy vice-chancellor (Research) professor Andrea Bishop said that the funding from NHMRC would enable the university to strengthen a range of important research projects.

It also allows the university to become a research institution that delivers research outcomes of real consequence.

Bishop further added: “This funding supports both ongoing and new projects in the university across a wide range of health disciplines.”

NHMRC has funded $2,735,991.5 for a project titled ‘A multicentre randomised controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in gay and bisexual men’.

Griffith team secured $715,060 for the ‘Self-assembling, self-adhering nerve bridges for large gap peripheral nerve injuries’ project, which is led by associate professor James St John.

Another $905,080 was awarded for the ‘How alphaviruses cause chronic, persistent joint disease (Professor Richard Bucala, Yale University, US)’ project.

Other projects that received the funding are ‘Difficult peripheral intravenous catheter insertion: Australian considerations for sustainable implementation of ultrasound-guided procedures’ and ‘Understanding the impact of language ability on the transition from late adolescence to early adulthood: the Early Language in Victoria Study’.

In a separate statement, Griffith University announced plans to conduct a world-first trial for gonorrhoea vaccine, which will be led by the university’s Institute for Glycomics and the Kirby Institute at UNSW Sydney.

Valued at $2.7m, the study incorporates five Australian universities and three health districts and other providers to test if meningococcal B vaccine protects against gonorrhoea in gay and bisexual men.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena